Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
SLRX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: November 27, 2025
Report Source: 2025 3rd Quarter Report
Salarius Pharmaceuticals Inc. Stock Analysis SLRX
United States Health Care Nano Cap Report: Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Read More Salarius Pharmaceuticals Inc (SLRX) Chart
Key Statistics of Salarius Pharmaceuticals Inc (SLRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.71Volume
-P/E Ratio (TTM)
-52 Week Range
Market Cap
3.75MAvg. Volume
111.97KDividend Yield
-Financial Metrics & Statements of Salarius Pharmaceuticals Inc (SLRX)
FAQ's for Salarius Pharmaceuticals Inc (SLRX)
- According to Musaffa’s Shariah screening methodology, Salarius Pharmaceuticals Inc (SLRX) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Salarius Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Salarius Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Salarius Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Salarius Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Salarius Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.